7PL Stock Overview
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ProstaLund AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.07 |
| 52 Week High | kr0.31 |
| 52 Week Low | kr0.051 |
| Beta | 0.81 |
| 1 Month Change | 1.45% |
| 3 Month Change | -36.94% |
| 1 Year Change | -77.64% |
| 3 Year Change | -86.64% |
| 5 Year Change | n/a |
| Change since IPO | -63.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7PL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 8.4% | -0.4% | 1.9% |
| 1Y | -77.6% | -6.0% | 5.9% |
Return vs Industry: 7PL underperformed the German Medical Equipment industry which returned -6% over the past year.
Return vs Market: 7PL underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 7PL volatility | |
|---|---|
| 7PL Average Weekly Movement | 16.2% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7PL's share price has been volatile over the past 3 months.
Volatility Over Time: 7PL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 8 | Johan Wennerholm | prostalund.se |
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow soft stent; Oruflow, a urine flow meter; Dosi-Fuser, a disposable continuous infusion system; and Dosi-Flow, a gravitation unit with a flow regulator for dosing of medicines. The company also provides Schelin Catheter, an injection tool that allows the urologists to administer drugs into the prostate in a sterile way through the urethra.
ProstaLund AB (publ) Fundamentals Summary
| 7PL fundamental statistics | |
|---|---|
| Market cap | €7.37m |
| Earnings (TTM) | -€1.45m |
| Revenue (TTM) | €1.90m |
3.9x
P/S Ratio-5.1x
P/E RatioIs 7PL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7PL income statement (TTM) | |
|---|---|
| Revenue | kr22.21m |
| Cost of Revenue | kr6.55m |
| Gross Profit | kr15.65m |
| Other Expenses | kr32.66m |
| Earnings | -kr17.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 70.49% |
| Net Profit Margin | -76.60% |
| Debt/Equity Ratio | 2.4% |
How did 7PL perform over the long term?
See historical performance and comparison